RXL-TSM 10mg | Research Peptide | 99%+ Purity | CAS 218949-48-5 | RemedyX Labs

RXL-TSM 10mg — high-purity research peptide with independently verified 99%+ purity and a batch-specific Certificate of Analysis (COA) CAS 218949-48-5. Available for in-vitro research use from RemedyX Labs. Third-party tested, research use only.

RXL-TSM (Tesamorelin) is a synthetic analog of growth hormone-releasing hormone (GHRH), studied for its ability to stimulate endogenous growth hormone secretion via pituitary GHRH receptor activation. Research applications include models of visceral fat metabolism, IGF-1 signaling, and lipodystrophy-related endocrine studies. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.

Cited Research

  • Metabolic effects of a growth hormone-releasing factor in patients with HIV

    A randomized trial found daily tesamorelin significantly reduced visceral adipose tissue and improved triglyceride and adiponectin levels in HIV-infected patients.

    New England Journal of Medicine, 2008

    View source · Read our summary

  • A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation

    A dose-ranging trial showed tesamorelin produced dose-dependent reductions in trunk fat and IGF-1 elevations in HIV patients with abdominal fat accumulation.

    AIDS, 2005

    View source · Read our summary

  • Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

    A 52-week follow-up study found sustained visceral fat reductions and an acceptable metabolic safety profile with continued tesamorelin treatment in HIV patients.

    AIDS, 2008

    View source · Read our summary

  • Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

    A placebo-controlled RCT with safety extension showed tesamorelin significantly reduced visceral fat, with effects reversing upon treatment discontinuation.

    HIV Medicine, 2010

    View source · Read our summary

  • Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data

    A pooled analysis of two phase 3 RCTs (n=816) confirmed consistent, statistically robust visceral fat reductions and characterized tesamorelin's safety profile across diverse HIV populations.

    Clinical Infectious Diseases, 2010

    View source · Read our summary

  • Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men

    Tesamorelin increased GH pulse amplitude and IGF-1 in healthy men without significantly impairing insulin sensitivity, distinguishing it mechanistically from direct GH administration.

    Journal of Clinical Endocrinology & Metabolism, 2010

    View source · Read our summary

  • Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

    A controlled trial showed tesamorelin-driven IGF-1 elevation improved executive function and cognitive composite scores in adults with mild cognitive impairment and healthy older adults.

    Archives of Neurology, 2012

    View source · Read our summary

  • Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

    A randomized trial using MR spectroscopy demonstrated tesamorelin reduced both visceral adipose tissue and intrahepatic fat content in HIV-infected patients with abdominal fat accumulation.

    JAMA, 2014

    View source · Read our summary

  • Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

    A placebo-controlled trial in type 2 diabetes patients found tesamorelin elevated IGF-1 and reduced visceral fat without significantly worsening glycemic control parameters.

    PLOS ONE, 2017

    View source · Read our summary

  • Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    A 12-month multicentre RCT demonstrated tesamorelin produced significant, clinically meaningful reductions in intrahepatic fat in HIV patients with confirmed non-alcoholic fatty liver disease.

    The Lancet HIV, 2019

    View source · Read our summary

  • Efficacy and safety of tesamorelin in people with HIV on antiretroviral therapy

    Synthesizes randomized-trial evidence for body composition and safety.

    PubMed, 2024

    View source · Read our summary

  • Tesamorelin improves fat quality independent of changes in fat quantity

    Assesses qualitative adipose changes beyond volume reduction.

    PubMed, 2021

    View source · Read our summary

  • The Growth Hormone Releasing Hormone Analogue Tesamorelin and Skeletal Muscle Quality

    Examines muscle density and area during tesamorelin treatment.

    PubMed, 2019

    View source · Read our summary

  • Tesamorelin, a human growth hormone releasing factor analogue in HIV-associated lipodystrophy

    Reviews phase 3 evidence and safety in the approved clinical context.

    PubMed, 2009

    View source · Read our summary

Full research bibliography